Lipoprotein lipase deficiency due to long-term heparinization presenting as severe hypertriglyceridaemia in pregnancy

G.F. Watts¹, J. Cameron², A. Henderson³ and W. Richmond³

¹Department of Endocrinology and Chemical Pathology, United Medical and Dental Schools of Guy’s and St Thomas’ Hospitals, St Thomas’ Hospital, London SE1 7EH; ²Clinical Biochemistry Department, Severalls Hospital, Boxted Road, Colchester CO4 5HG; and ³Department of Chemical Pathology, St Mary’s Hospital, Praed Street, London W2 1NY, UK.

Summary: A case of severe hypertriglyceridaemia presenting in the third trimester of pregnancy in a woman on long-term heparin prophylaxis is described. The hypertriglyceridaemia was attributed to impaired clearance of triglyceride-rich lipoprotein particles secondary to heparin-induced reduction in the activity of the lipolytic enzyme, lipoprotein lipase.

Introduction

The use of low-dose heparin in the prophylaxis of thrombo-embolic disease is well established. Less well known is the effect of heparin on lipoprotein metabolism. An intravenous injection of heparin acutely lowers plasma triglyceride by liberating into the plasma the endothelial-bound lipolytic enzyme, lipoprotein lipase (LPL).¹ On the other hand, it has been suggested that prolonged administration of heparin may impair triglyceride clearance owing to depletion of the tissue stores of LPL.² This phenomenon has, however, not yet been demonstrated in vivo. The rise in plasma oestrogen concentration in pregnancy can also disturb the metabolism of triglyceride-rich lipoproteins and in patients with a primary deficiency in LPL often results in severe hyperchylomicronaemia and acute pancreatitis.³ The following report describes the influence of chronic administration of heparin on triglyceride metabolism during and after pregnancy.

Case report

At 4 weeks gestation during her third pregnancy, a 40 year old woman accidentally fell and fractured her right tibia and fibula, which were subsequently immobilized in plaster of Paris for 6 months. Three weeks after removal of the plaster she was admitted to hospital with dyspnoea, pleuritic chest pain and haemoptysis. The clinical diagnosis of pulmonary embolism was made and following full anticoagulation with intravenous heparin for 10 days, she was discharged on prophylactic heparin, 10,000 units subcutaneously twice daily.

At 30 weeks gestation a blood sample sent to the laboratory for routine oestriol estimation was found to be grossly lipaemic and she was referred to the lipid clinic, from where she was admitted to hospital for further investigation. The plasma concentrations of cholesterol and triglyceride were grossly elevated at 40.0 mmol/l and 160 mmol/l, respectively; lipoprotein fractionation revealed excessive accumulation of chylomicrons and very low density lipoproteins (Frederickson type V phenotype). There were no xanthomata and the liver and spleen were not palpable. Her father had died from a stroke aged 52 years and her mother from cancer. Her only brother refused a blood test, but 2 teenage children were normolipidaemic. The blood pressure was normal (110/70 mmHg) and there was no proteinuria. Fasting blood glucose, liver and thyroid function, and renal biochemistry were all within normal limits. Plasma heparin activity was 0.30 IU/ml 1 h pre-injection.

The heparin regimen was continued and after 10 days on a 25 g fat, 2000 kcal diet the plasma concentration of triglyceride fell to 20 mmol/l (Figure 1). The LPL activity was then specifically measured in post-heparin plasma (40 units/kg given intravenously) after inactivation of hepatic lipase with sodium dodecyl sulphate⁴: the plasma LPL activity was 0.2 μmol of free fatty acids/ml/h.

Correspondence: G.F. Watts, B.Sc., D.M., M.R.C.P.
Accepted: 1 August 1991
Dietary intake per day: 2000 kcal, 25 g fat
Heparin: 10,000 units sc bd

![Graph showing plasma triglyceride levels](image)

**Figure 1** Plasma concentration of triglyceride in relation to pregnancy, heparin therapy and a low fat diet in a woman who presented with severe chylomicronaemia at 30 weeks gestation.

The plasma fat removal capacity was also measured by an intravenous fat tolerance test: the disappearance rate (K₂) of a 10% emulsion of Intralipid (1 ml/kg) was 1.4%/min (reference range 4.2–11.2).

She remained asymptomatic for the rest of pregnancy and at 38 weeks gestation spontaneously gave birth to a 3 kg, healthy boy; the plasma triglyceride concentration in cord blood was 0.14 mmol/l. She did not breast feed. She continued taking heparin 10,000 subcutaneously, twice daily until 3 months post-partum and a 25 g fat, 2000 kcal diet for a further 3 months. Whilst receiving heparin (plasma activity 0.28 IU/ml 1 h pre-injection) the mean plasma concentration of triglyceride was 20 mmol/l, but fell to less than 10 mmol/l after stopping heparin (Figure 1). LPL activity in post-heparin plasma and the K₂ of Intralipid were both suppressed 10 weeks post-partum, but became normal 10 weeks after heparin was discontinued (Figure 2); heparin-releasable hepatic lipase activity also showed similar changes, only reverting to normal (15 μmol of free fatty acids/ml/h) after stopping heparin. A year later while on an isocaloric, fat-modified (66 g total fat) diet the plasma concentration of cholesterol and triglyceride remained slightly elevated at 7.0 mmol/l and 3.5 mmol/l, respectively.

**Discussion**

This case demonstrates for the first time that prolonged use of subcutaneous heparin may result in a profound disturbance of lipoprotein metabolism. We suggest that the mechanism for the decrease in clearance of triglyceride-rich lipoproteins is that long-term heparinization induced continuous release and subsequent degradation of LPL that exceeded the synthetic rate of the enzyme. This causal connection could have been tested further by re-challenging the patient with heparin 6 months post-partum, but the experiment was not considered ethical. Our findings are, however, consistent with other clinical observations showing that renal failure patients receiving haemodialysis and frequent heparinization often develop hypertriglyceridaemia and a reduced fractional catabolic rate of Intralipid. Continuous, intravenous heparin for 6 days has also been reported to reduce the clearance rate of Intralipid in non-renal failure patients. None of these studies, however, measured LPL activity.

The pronounced chylomicronaemia at presentation was probably compounded by the oestrogenic response to pregnancy, since this increases hepatic secretion of very low density lipoproteins. The
hormonal changes in pregnancy do not appear to influence LPL activity in humans.3,10,11 suggesting that our biochemical findings in this patient were primarily attributed to heparin and not to an effect of pregnancy. Oestrogens have, however, been shown to reduce LPL activity in adipose tissue of the rat.12

As in this report, severe chylomicronaemia in pregnancy may also be seen in patients with familial hypertriglyceridaemia13 or familial LPL deficiency,3,14 in whom acute pancreatitis has often been described. We emphasize that the risk of pancreatitis due to hyperchylomicronaemia in pregnancy may be mitigated by assiduous attention to diet alone. In this context it is noteworthy that a previously reported patient with familial LPL deficiency developed recurrent pancreatitis in pregnancy despite the apparent elimination of fat from the diet.3

From a practical viewpoint, we suggest that women receiving long-term heparin prophylaxis during pregnancy should have their plasma lipids quantified or, at least, the plasma from a fasting blood sample be visually examined for latescence. A plasma lipid screen prior to commencing treatment may also be useful in identifying those most susceptible to impairment of the clearance of triglyceride-rich lipoproteins. Should severe hypertriglyceridaemia develop it may be controlled with a low fat diet without the need to discontinue heparin.

Acknowledgement

We are grateful to Mr W. Jefferson for typing the manuscript.

References